Joint Formulary & PAD

Etoricoxib - Pain and inflammation - musculoskeletal

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Etoricoxib
Indication :
Pain and inflammation - musculoskeletal
Group Name :
Keywords :
COXIIs, Coxib, Cox-2, cyclo-oxygenase-2, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis, PNMP
Brand Names Include :
Arcoxia
Important Information :

2nd line COXX II except for gouty arthritis where etoricoxib is the preferred COX II

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey & North West Sussex Area Prescribing Committee recommends etoricoxib as a treatment option for the treatment of pain and inflammation in line with the product licence*.

Etoricoxib will be considered as GREEN on the traffic light system as a 2nd line COX-2 inhibitor (after celecoxib) for use where a COX-2 inhibitor is indicated.

If etoricoxib is indicated for the treatment of gouty arthritis then etoricoxib should be considered before celecoxib as it is licensed for this indication.

*Licenced for: Osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute gouty arthritis

The branded product, Arcoxia, is considered BLACK. Please prescribe generically for this indication.

Other Indications

Below are listed other indications that Etoricoxib is used to treat.